Waiv, previously the diagnostics division of AI biotech Owkin, developed AI-enabled testing applied sciences that discovered use in medical settings and in most cancers drug analysis. Spinning out as an unbiased firm allows Waiv to pursue its personal development technique, co-founder and CEO Meriem Sefta stated.
The submit Startup Waiv Spins Out of Owkin With $33M to Carry AI Precision to Most cancers Choices appeared first on MedCity Information.
